Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 8/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11698967 | 0.93 | EPHX1 (0.62) | EPHX1LMNAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL14008172 | 0.91 | EPHX1 (0.66) | EPHX1ALDH1A1POLBSMN1; SMN2CASP2 | |
| SCHEMBL22472041 | 0.91 | EPHX1 (0.66) | EPHX1ALDH1A1POLBSMN1; SMN2CASP2 | |
| SCHEMBL14008166 | 0.91 | EPHX1 (0.66) | EPHX1ALDH1A1POLBSMN1; SMN2CASP2 | |
| SCHEMBL2797759 | 0.86 | MMP1 (0.43) | EPHX1LMNAMMP2ALDH1A1POLB | |
| SCHEMBL14008176 | 0.85 | EPHX1 (0.49) | EPHX1ACHEALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL13660344 | 0.83 | MEN1 (0.58) | EPHX1LMNAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL13660337 | 0.83 | MEN1 (0.58) | EPHX1LMNAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL13660345 | 0.83 | MEN1 (0.58) | EPHX1LMNAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL28283984 | 0.83 | EPHX1 (0.50) | EPHX1ACHEMMP2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115246791-B | Method for synthesizing 6-trifluoromethyl uracil and intermediate thereof | 内蒙古世杰化工有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-115246791-A | Method for synthesizing 6-trifluoromethyl uracil and intermediate thereof | 四川奥兰多化工有限公司 | 2022-10-28 | — | — | CN | disclosed |
| WO-2020196553-A1 | METHOD FOR PRODUCING N-SUBSTITUTED TRIHALOACETAMIDE | 国立大学法人神戸大学 | 2020-10-01 | — | — | WO | disclosed |
| WO-2020196553-A1 | METHOD FOR PRODUCING N-SUBSTITUTED TRIHALOACETAMIDE | 国立大学法人神戸大学 | 2020-10-01 | — | — | WO | disclosed |
| EP-2670419-A1 | PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF | Integrated Diagnostics Inc. (US) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012106671-A1 | PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF | INTEGRATED DIAGNOSTICS, INC. (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| EP-2117603-A2 | TARGETING AND THERAPEUTIC COMPOUNDS AND GAS-FILLED MICROVESICLES COMPRISING SAID COMPOUNDS | BRACCO INTERNATIONAL B.V. (NL) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008075192-A2 | TARGETING AND THERAPEUTIC COMPOUNDS AND GAS-FILLED MICROVESICLES COMPRISING SAID COM OUNDS | BRACCO INTERNATIONAL BV (NL) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153838-A1 | Compounds Having Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| EP-1654218-A2 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016868-A2 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| EP-0842927-B1 | 3-Amido-chromanylsulfonyl(thio)ureas, process for their preparation, their use and medicaments containing them | AVENTIS PHARMA GMBH (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-5849755-A | 3-amidochromanylsulfonyl(thio)ureas, processes for their preparation, their use, and pharmaceutical preparations comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-15 | — | — | US | disclosed |
| EP-0842927-A1 | 3-Amido-chromanylsulfonyl(thio)ureas, process for their preparation, their use and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153838-A1 | Compounds Having Tie2 (Tek) Activity | TEK, TIE1, KDR | EPHX1 2323/4885LMNA 615/4885ACHE 3786/4885 |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | TEK, TYMP, TIE1 | EPHX1 1321/4885LMNA 2014/4885ACHE 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.